SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Hillert J) "

Search: WFRF:(Hillert J)

  • Result 961-970 of 1165
Sort/group result
   
EnumerationReferenceCoverFind
961.
  •  
962.
  •  
963.
  •  
964.
  •  
965.
  •  
966.
  • Longinetti, E., et al. (author)
  • COVID-19 clinical outcomes and DMT of MS patients and population-based controls
  • 2022
  • In: Annals of Clinical and Translational Neurology. - : Wiley. - 2328-9503. ; 9:9, s. 1449-1458
  • Journal article (peer-reviewed)abstract
    • Objective: To estimate risks for all-cause mortality and for severe COVID-19 in multiple sclerosis patients and across relapsing-remitting multiple sclerosis patients exposed to disease-modifying therapies. Methods: We conducted a Swedish nationwide population-based multi-register linkage cohort study and followed all multiple sclerosis patients (n = 17,692 in March 2020), individually age-, sex-, and region-matched to five population-based controls (n = 86,176 in March 2020) during March 2020-June 2021. We compared annual all-cause mortality within and across cohorts, and assessed incidence rates and relative risks for hospitalization, intensive care admission, and death due to COVID-19 in relation to disease-modifying therapy use, using Cox regression. Results: Absolute all-cause mortality among multiple sclerosis patients was higher from March to December 2020 than in previous years, but relative risks versus the population-based controls were similar to preceding years. Incidence rates of hospitalization, intensive care admission, and death due to COVID-19 remained in line with those for all-cause hospitalization, intensive care admission, and mortality. Among relapsing-remitting patients on rituximab, trends for differences in risk of hospitalization due to COVID-19 remained in the demographics-, socioeconomic status-, comorbidity-, and multiple sclerosis severity-adjusted model. Interpretation: Risks of severe COVID-19-related outcomes were increased among multiple sclerosis patients as a whole compared to population controls, but risk increases were also seen for non-COVID-19 hospitalization, intensive care admission, and mortality, and did not significantly differ during the pandemic compared to pre-pandemic years. The risk conveyed by disease-modifying therapies was smaller than previously assumed, likely as a consequence of the possibility to better control for confounders.
  •  
967.
  •  
968.
  • Lundkvist, M., et al. (author)
  • Characterization of anti-natalizumab antibodies in multiple sclerosis patients
  • 2013
  • In: Multiple Sclerosis Journal. - : SAGE Publications. - 1352-4585 .- 1477-0970. ; 19:6, s. 757-764
  • Journal article (peer-reviewed)abstract
    • Background: A small proportion of multiple sclerosis (MS) patients treated with natalizumab develop anti-drug antibodies. Objective: The objective of this paper is to characterize the anti-natalizumab antibody response and to investigate differences between persistently and transiently antibody-positive patients. Methods: Screening for anti-natalizumab antibodies was performed using a standardized bridging ELISA. Antibody-positive samples were further analyzed for IgM and IgG1-4 antibodies using ELISA and ImmunoCAP (R). Results: Anti-natalizumab antibodies developed in 57 of 1379 (4.1%) treated patients after a median treatment duration of three months. Of the positive patients, 20 (35%) patients reverted to negative, 19 (33%) patients were confirmed persistently positive and 18 (32%) patients were unconfirmed positive. Significantly higher anti-natalizumab antibody levels were detected in persistently compared to transiently positive patients. A cutoff value predicting persistence of antibodies could be determined with a sensitivity of 0.84 and a specificity of 0.80. IgM and IgG4 antibody levels were significantly higher in persistently compared to transiently positive patients, and IgG1, IgG2 and IgG4 increased significantly over time. Conclusions: The level of total anti-natalizumab antibodies in a first positive sample can be used to predict patients at risk for persisting antibody positivity. However, neither IgM nor IgG1-4 antibodies could be used to discriminate between transiently and persistently positive patients.
  •  
969.
  •  
970.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 961-970 of 1165
Type of publication
journal article (719)
conference paper (317)
book (1)
research review (1)
Type of content
peer-reviewed (758)
other academic/artistic (399)
Author/Editor
Nilsson, P. (453)
Lohse, T. (422)
Backes, M. (396)
Berge, D. (392)
Ma, H. (376)
Aleksa, M. (375)
show more...
Antonaki, A. (375)
Baker, O. K. (375)
Beck, H. P. (375)
Boonekamp, M. (375)
Carli, T. (375)
Catinaccio, A. (375)
Chen, H. (375)
Chen, X. (375)
Davidek, T. (375)
Di Girolamo, B. (375)
Farbin, A. (375)
Fassouliotis, D. (375)
Ferrer, A. (375)
Fournier, D. (375)
Francis, D. (375)
Ghodbane, N. (375)
Giokaris, N. (375)
Gorini, B. (375)
Hajduk, Z. (375)
Hakobyan, H. (375)
Hance, M. (375)
Hervas, L. (375)
Hostachy, J-Y. (375)
Hughes, G. (375)
Khoriauli, G. (375)
Korolkov, I. (375)
Lafaye, R. (375)
Lai, S. (375)
Laplace, S. (375)
Lokajicek, M. (375)
Lucotte, A. (375)
Martin, B. (375)
McFarlane, K. W. (375)
Mouraviev, S. V. (375)
Olszowska, J. (375)
Pallin, D. (375)
Petersen, T. C. (375)
Poveda, J. (375)
Prieur, D. (375)
Rembser, C. (375)
Riu, I. (375)
Santoni, C. (375)
Sauvage, G. (375)
Schmitt, C. (375)
show less...
University
Karolinska Institutet (691)
Stockholm University (277)
Uppsala University (253)
Lund University (250)
Royal Institute of Technology (248)
Linnaeus University (47)
show more...
Örebro University (44)
Umeå University (23)
University of Gothenburg (18)
Linköping University (6)
Red Cross University College (2)
Mid Sweden University (1)
Chalmers University of Technology (1)
show less...
Language
English (1164)
Swedish (1)
Research subject (UKÄ/SCB)
Natural sciences (286)
Medical and Health Sciences (122)
Engineering and Technology (3)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view